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In mice and humans the circadian rhythm of many biochemical
reactions, physiology, andbehavior is generatedbya transcriptional-
translation feedback loop (TTFL) made up of the so-called core clock
genes/proteins. The circadian system interfaces with most signaling
pathways including those involved in cell proliferation and in-
flammation. Cryptochrome (CRY) is a core clock protein that plays
an essential role in the repressive arm of the TTFL. It was recently
reported that mutation of CRY in p53-null mice delayed the onset
of cancer. It was therefore suggested that CRY mutation may
activate p53-independent apoptosis pathways, which eliminate
premalignant and malignant cells and thus delay overt tumor
formation. Here we show that CRY mutation sensitizes p53 mutant
and oncogenically transformed cells to tumor necrosis factor α
(TNFα)-initiated apoptosis by interfacing with the NF-κB signaling
pathway through the GSK3β kinase and alleviating prosurvival
NF-κB signaling. These findings provide a mechanistic foundation
for the delayed onset of tumorigenesis in clock-disrupted p53 mu-
tant mice and suggest unique therapeutic strategies for treating
cancers associated with p53 mutation.
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The circadian rhythm in mammalian organisms is generated bya molecular clock comprising four gene/protein groups (1–5):
The CLOCK (NPAS2) and BMAL1 transactivators and the
cryptochrome 1 and 2 (CRY1/2) and the period 1 and 2 (PER1/
2) repressors. CLOCK (or NPAS2) and BMAL1 make hetero-
dimers, which act on the promoters of CRY1/2 and PER1/2 and
activate their transcription. The CRY and PER proteins in turn,
after a time delay of ill-defined mechanism, inhibit the CLOCK-
BMAL1 transactivator and hence their own transcription to
close the TTFL. This core TTFL directly or indirectly affects
most cellular functions, and as a result, clock disruption by core
clock gene mutation is expected to have serious repercussions at
the cellular and organismal levels.
We recently reported that mice of the p53−/−Cry1−/−Cry−/−
(hereafter p53KOCryDKO) genotype exhibited delayed onset of
spontaneous cancer relative to p53−/− (p53KO) mice (6). When
analyzed for their response to genotoxic stress, it was found that
p53KOCryDKO cells were more sensitive to UV-induced apoptosis
than p53KO cells even though they are identical in terms of DNA
repair and DNA damage checkpoint functions (6). Therefore, we
ascribed the reduced clonogenic survival of p53KOCryDKO cells
upon UV irradiation, relative to p53KO cells, to enhanced p53-
independent apoptosis as a consequence of CRY mutation. We
also suggested that the delayed onset of cancer and prolonged
lifespan of mice of p53KOCryDKO genotype may have been caused
by enhanced apoptosis of oncogenically transformed cells before
giving rise to macroscopic tumors (6). In line with these findings
we recently determined that p53KOCryDKO tumors are more re-
sponsive to oxaliplatin than p53KO tumors (7). However, UV and
oxaliplatin activate the intrinsic apoptosis pathway (8) that is
commonly induced by DNA damaging agents, whereas the dif-
ference in tumor incidence between the two mouse lines was
observed in the absence of any external genotoxic stress.
Therefore, we considered the possibility that the loss of CRY
may amplify the extrinsic pathway for apoptosis to eliminate cells
with potential to give rise to cancer. Here we present evidence
that the circadian clock and NF-κB signaling pathway intersect
and that CRY mutation enhances extrinsic apoptosis by in-
terfering with NF-κB–mediated activation of transcription of
genes required for antiapoptosis upon cytokine stimulation.
Results
Effect of the Circadian Clock on Extrinsic Apoptosis Induced by TNFα.
To find out whether CRY mutation sensitizes cells to the ex-
trinsic apoptosis pathway, we treated p53KO and p53KOCryDKO
dermal fibroblasts (6) with tumor necrosis factor α (TNFα),
which is one of the key inflammatory cytokines known to activate
the extrinsic apoptosis pathway (9–11). As apparent from Fig.
1A, the cytokine elicits remarkably enhanced apoptotic response
in p53KOCryDKO cells as measured by the extent of proteolytic
cleavage of poly ADP ribose polymerase (PARP) and caspase 3.
Importantly, this increased sensitivity to apoptosis is reflected in
cell viability as measured by clonogenesis assay (Fig. 1B), sug-
gesting that the enhanced apoptosis may play a role in prefer-
ential elimination of CRY-null cancer cells exposed to cytokines.
Next, we wished to determine whether the enhanced sensitivity
to TNFα-induced apoptosis and the associated reduction in
clonogenic survival were the phenotypic manifestation of CRY
mutation independent of its role in the core circadian clock
circuitry or a reflection of its role in the molecular clock. To this
end, either CRY1/2 alone or both CRY1/2 (negative arm) and
BMAL1 (positive arm) were down-regulated in p53KO cells and
then the cells were treated with TNFα and analyzed for apoptosis
and clonogenicity. As seen in Fig. 1C, depletion of CRY1/2 by
siRNA in p53KOCryDKO cells has essentially the same conse-
quence as null mutations of these genes in p53KOCryDKO cells
(Fig. 1A) in terms of TNFα-induced apoptosis and clonogenic
survival (Fig. 1D). Importantly, depletion of BMAL1 as well
negates the enhanced apoptosis and clonogenic lethality pro-
moted by CRY1/2 down-regulation (Fig. 1 C and D). Thus, we
conclude that in p53KO cells the core circadian clock strongly
influences the extent of TNFα-induced apoptosis.
Role of NF-κB in Linking the Circadian Clock to Extrinsic Apoptosis.
Next, we wished to determine the point at which the clock inter-
faces with the TNFα-initiated apoptosis pathway. It is well estab-
lished that the NF-κB transcription factor plays a critical role in
immune responses stimulated by inflammatory cytokines such as
TNFα and IL-1β (12, 13). In addition, NF-κB has also been shown
to have a role in cellular transformation and tumorigenesis by up-
regulating the expression of some antiapoptosis genes upon in-
flammatory cytokine stimulation (14, 15). The effect of NF-κB on
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tumorigenesis, however, is strongly modulated by the p53 tumor
suppressor, which can antagonize NF-κB activity (16–18). In p53-
null background, the NF-κB signaling pathway has been shown to
promote cell proliferation throughNF-κB–mediated transcription
of antiapoptotic factors and thus promote tumor growth (18).
Conversely, inhibition of NF-κB signaling in a p53-null tumor
model resulted in robust cell death by apoptosis (18), suggesting
a potential approach for selectively eliminating p53-null cancer
cells by interfering with NF-κB signaling.
To analyze the role of NF-κB in TNFα-induced apoptosis, the
RelA subunit of NF-κB heterodimer (RelA-p50) was down-
regulated in p53KO and p53KOCryDKO cells by siRNA; the cells
were then treated with TNFα and probed for apoptosis, using
PARP and caspase 3 cleavages as readout (Fig. 2). We found that
whereas knockdown of RelA in p53KOCryDKO cells, which have
heightened apoptotic response to the cytokine already, has no
further effect on the level of apoptosis and cell viability, down-
regulation of RelA in the in p53KO cells enhanced the extent of
apoptosis and lethality to a level comparable to that seen in
p53KOCryDKO cells (Fig. 2 A and B). These results support the view
that NF-κB plays an important role in the suppression of TNFα-
initiated apoptosis in p53-null cells and suggest that the TNFα–
NF-κB–apoptosis signaling pathway is controlled by the circadian
clock. It is known that NF-κB activates the transcription of anti-
apoptotic genes such as IAPs to suppress TNFα-initiated apo-
ptosis in the tumor cells (14, 15, 19). Hence, to assess the effect of
CRY on this signaling axis, we treated cells with TNFα or IL-1β
to activate the NF-κB pathway (12, 20) and measured the tran-
scriptional activation of NF-κB target genes IAP2 and ICAM. As
expected, both cytokines induce transcription of these genes in
p53KO cells (Fig. 2C). Importantly, in the p53KOCryDKO background,
the cytokine-initiated transcriptional activation of NF-κB target
genes was abolished (Fig. 2C).Moreover, the similar effects of CRY
mutation on NF-κB activation by both TNFα and IL-1β (Fig. 2C)
indicate that CRY affects the NF-κB signaling pathway in general.
Furthermore, the effect of CRY mutation on TNFα-stimulated
transcription of IAP2 and ICAM is reversed by down-regulating
BMAL1 (Fig. 2D), indicating that the observed effect of CRY
mutation on the cytokine–NF-κB signaling axis is not due to
a nonclock function of CRY, but is a manifestation of interfacing of
the core circadian clock with the NF-κB signaling pathway.
This conclusion was further confirmed by analyzing the occu-
pancy of the IAP2 and ICAM promoters by NF-κB using the
chromatin immunoprecipitation (ChIP) assay with antibodies
against the RelA subunit of the NF-κB heterodimer. As seen in
Fig. 2E, TNFα stimulates binding of NF-κB to the promoters of
both IAP2 and ICAM in p53KO cells and this stimulation is
nullified by CRY mutation. Furthermore, in agreement with the
transcription data in Fig. 2C, down-regulation of BMAL1 in
p53KOCryDKO cells restores the TNFα-induced occupancy of NF-
κB in the promoters of its target genes (Fig. 2F). Thus, we
conclude that the core circadian clock activity regulates the NF-
κB pathway and hence apoptosis in response to cytokine stimu-
lation in p53-impaired cells, with the negative arm of the clock
(CRY) inhibiting and the positive arm (BMAL1) promoting
apoptosis in this genetic background.
Role of GSK3β in Linking the Circadian Clock to the Proapoptotic NF-
κB Signaling. The data presented so far establish a link between
the NF-κB activity and the circadian clock but does not provide
an insight into the nature of this association. We considered
GSK3β kinase as a potential candidate to link the two systems
because GSK3β is known to activate NF-κB (21, 22) and, re-
cently, it was reported that the phosphorylated (inactive) form of
GSK3β exhibited a circadian rhythm in the mouse liver with the
inactive GSK3β-P in phase with BMAL1 and antiphase with
CRY1 (23). Hence, we wished to determine how the interfacing
of the molecular clock with NF-κB through GSK3β would impact
the cytokine-initiated apoptosis in p53-null cells with a functional
or disrupted circadian clock. As apparent in Fig. 3A, in CRY-null
cells the level of phosphorylated GSK3β is elevated without
measureable change in the overall level of GSK3β and without
a noticeable impact of the p53 status of the cell. Moreover, this
effect appears to be the consequence of the core clock function
of CRY because it is abolished by down-regulation of BMAL1 in
CRY-null cells (Fig. 3B).
To gain some insight into the mechanism by which the circadian
TTFL controls the activity of GSK3β, we treated p53KOCryDKO
cells with either the protein synthesis inhibitor cycloheximide or
the transcription inhibitor actinomycin D and examined the levels
of GSK3β and phospho-GSK3β over a 6-h period. We found that,
whereas there was no significant change in GSK3β levels over the
course of the experiment, the phospho-GSK3β levels decayed with
a half-life of ∼1 h when either translation or transcription was
inhibited (Fig. 3C). As a relatively short half-life of a protein or of
its activity is essential for a robust circadian rhythmicity, this
finding supports the report of strong circadian oscillation of
GSK3β activity without a measurable change in the total GSK3β
level in the mouse liver. Thus, we conclude that GSK3β activity is
a bona fide clock-controlled function.
To examine the contribution of clock-controlled GSK3 activity
on the cytokine-mediated NF-κB activation and the subsequent
apoptotic response, we treated the p53KOCryDKO cells with so-
dium nitroprusside (SNP), which is known to activate GSK3β
Fig. 1. Regulation of cytokine-initiated apoptosis by the circadian clock. (A
and B) Effect of cryptochrome. (A) Immunoblots showing the apoptotic in-
dex probed with the indicated antibodies. Dermal fibroblasts of the in-
dicated genotypes were treated with TNFα (50 ng/mL) for 48 h and then cell
lysates were analyzed by immunoblotting. Actin was examined as a loading
control. (B) Clonogenic cell survival assay showing the viable cells remaining
after treatment with TNFα (50 ng/mL) for 48 h as a percentage of viable
untreated cells. Results represent the mean of three independent experi-
ments (±SD). (C and D) Contribution of BMAL1. (C) Apoptotic index. p53KO
cells were transfected with the indicated siRNAs and then incubated with
TNFα (50 ng/mL) for 48 h, followed by lysis and immunoblotting. (D) Clo-
nogenic cell survival assay was used to determine cell viability of p53KO cells
transfected with the indicated siRNAs and then treated with TNFα for 48 h,
diluted, and plated. (±SD, n = 3).











through dephosphorylation (24–26) (Fig. S1) and analyzed the
transcription of IAP2 and ICAM (Fig. 3D), apoptotic proteolysis
of PARP and caspase 3 (Fig. 3E), and cell viability (Fig. 3F) in
response to TNFα. The data reveal that SNP-mediated accu-
mulation of dephosphorylated GSK3β leads to enhanced tran-
scription of IAP2 and ICAM (Fig. 3D), decreased apoptotic
response to TNFα (Fig. 3E), and reduced clonogenic lethality of
TNFα (Fig. 3F). Taken together, the data in Fig. 3 lead to the
conclusion that the circadian clock, through the intermediating
of GSK3β, gates the cytokine-mediated antiapoptotic function of
NF-κB. Fig. 3G summarizes the mechanistic findings of our
study: In p53 mutant cells with a functional clock, inflammatory
cytokines such as TNFα activate the transcription of anti-
apoptotic genes in a manner gated by the circadian clock through
GSK3β phosphorylation. In contrast, the CRY-null mutation in
p53 dysfunctional cells leads to hyperphosphorylation and in-
activation of GSK3β and failure to phosphorylate and activate
the antiapoptotic effect of NF-κB, making cells more sensitive to
TNFα-induced apoptosis.
Cryptochrome, TNFα, and Hepatocellular Carcinoma (HCC). Recent
studies have revealed that TNFα supports the growth of HCC, a
prototype of inflammation-associated cancer (27), through acti-
vation of NF-κB–dependent expression of antiapoptotic genes
(15). In addition, the loss of p53 functionality has been shown to
be closely correlated with the severity of HCC (28, 29). Hence, to
test for clock disruption as a potential therapeutic approach for
HCC we investigated the effect of CRY down-regulation on
cytokine-induced apoptosis in HCC cell lines without and with
p53 functionality. In the p53 mutant Hep3B HCC cell line, down-
regulation of CRY significantly reduced the transcription of NF-
κB–dependent genes upon TNFα stimulation (Fig. 4A), potenti-
ated TNFα-induced apoptosis (Fig. 4B) and loss of viability
(Fig. 4C). In contrast, the down-regulation of CRY in the HepG2
HCC cell line with wild-type p53 does not affect the level of
TNFα-induced apoptosis (Fig. 4D), presumably because in this
genetic background the contribution of p53 to the apoptotic re-
sponse to the cytokine is so robust that further enhancement by
CRY down-regulation cannot be detected.
As a further proof of principle that CRY inhibition or dis-
ruption can be used as a therapeutic modality in p53 mutant
tumors we performed the following experiment: Immunodefi-
cient mice were s.c. injected with untreated or TNFα-treated
p53KO cells on the left flank and untreated or TNFα-treated
p53KOCryDKO cells on the right flank, and tumor growth and
metabolism were monitored (Fig. 5). As seen in Fig. 5A, the
tumors arising from cells of the p53KO and p53KOCryDKO geno-
types grow at the same rate in the absence of TNFα treatment.
However, the TNFα-treated p53KOCryDKO tumors grow slower
(Fig. 5A) and have reduced metabolic activity (Fig. 5B) com-
pared with their p53KO counterparts. We note, however, the
limitation of this assay in that TNFα-treated cells were used for
tumorigenesis rather than administering TNFα systemically after
tumors had reached a certain size. However, systemic treatment
Fig. 2. Regulation of NF-κB activity by the circadian clock. (A and B) Apoptosis and clonogenic death. (A) Apoptosis. Immunoblots of extracts from p53KO and
p53KOCryDKO cells transfected with the indicated siRNAs and then treated with TNFα (50 ng/mL) for 48 h. (B) Viability. Cells were transfected with siRNAs as
indicated and then treated with TNFα (50 ng/mL, 48 h), diluted, and plated. Survival was determined by clonogenic assay (±SD, n = 3). *P < 0.005. (C and D)
Transcription. Regulation of target genes of NF-κB by the clock. Quantitative real-time PCR analysis following TNFα (50 ng/mL, 1 h) or IL-1β (30 ng/mL, 1.5 h) of
the indicated cell lines without (C), and with (D) siRNA transfections as indicated.*P < 0.005, **P < 0.001. (E and F) Promoter binding. Regulation by the clock
of the occupancy of the promoters of NF-κB target genes was probed by ChIP with RelA antibodies following TNFα treatment of p53KO and p53KOCryDKO cells
(E) and of the p53KOCryDKO cells transfected with the indicated siRNAs (F). RelA occupancy of the promoters relative to the untreated control is shown. Data
represent means ± SD (n = 3). *P < 0.005, **P < 0.001.
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of tumors with TNFα in this experimental system is not feasible
because the doses necessary to achieve effective concentrations
in the tumor are toxic to the mice. Nevertheless, these data raise
the possibility that with appropriate cytokine delivery regimens
CRY inhibition may be used as an adjuvant to treatment of
certain tumors with cytokines.
Conclusion
This study was undertaken, in part, to understand the molecular
basis for the delayed onset of cancer in p53KOCryDKO mice rel-
ative to p53KO mice. We believe that our data in this paper have
provided a plausible explanation: The clock disruption through
CRY mutation sensitizes the transformed cells to apoptosis by
inflammatory cytokines such as TNFα, which is known to be el-
evated in CRY mutant mice (30). Our findings also link two
major signaling pathways, the circadian clock, which introduces
a temporal variable into many cellular and physiological func-
tions, and the NF-κB pathway, which is a key nodal focus in the
inflammatory response at a cellular and organismal level. Finally,
our data suggest potential therapeutic approaches for treating
p53 mutation-associated cancers by targeting the clock in general
and cryptochrome in particular.
Materials and Methods
Establishment of Dermal Fibroblast Cell Lines. Wild-type and p53KO mice of
C57BL/6J background were obtained from The Jackson Laboratory. Crypto-
chrome mutants in C57BL/6J background, p53KO and p53KOCryDKO were
generated in our laboratory as described previously (6, 31). The mice were
handled in accordance with the guidelines of the National Institutes of
Health and the University of North Carolina School of Medicine. Dermal
fibroblasts were isolated using skin biopsy as described previously (6).
Cell Lines, siRNA, and Reagents. Hep3B and HepG2 cells were obtained from
American Type Culture Collection. These cells and dermal fibroblasts isolated
in our laboratory were grown in Dulbecco’s Modified Eagle Medium (Gibco),
supplemented with 10% FBS (Gibco) and 100 units/mL penicillin and 100
μg/mL streptomycin (Gibco). DharmaFECT (Dharmacon) reagent was used
according to the manufacturer’s instruction for transcfection of ON-TARGET
plus SMARTpool siRNA duplexes obtained from Dharmacon [mCry1 (L-
040485-01-0005), mCry2 (L-040486-00-0005), mBMAL1 (L-040483-01-0005),
mRelA (L-040776-00-0005), mGSK3β (L-041080-00-0005), mCyclophilin-B (D-
001820-20-05), hCry1 (L-015421-00-0005), hCry2 (L-014151-01-0005), hCyclo-
philin-B (D-001820-10-05), or nontargeting siRNA (D-001810-10-05) as a con-
trol]. For Fig. 3C, cells were treated with 20 μg/mL cycloheximide (Sigma) or
5 μg/mL actinomycin D (Sigma) for the indicated times before analysis by
immunoblotting. For Fig. 3 D–F, cells were treated with 2 mM SNP (Calbio-
chem) for 20 min before treatment of TNFα (50 ng/mL). The specificity of the
antibodies and siRNAs used are shown in Fig. S2.
Immunoblotting. Protein levels from whole cell lysate were determined by
immunoblotting. Antibodies used in this study include those for RelA, Actin,
Cyclophilin B, and IgG control (Santa Cruz Biotechnology), cleaved-caspase3,
PARP1, GSK3β, phospho-GSK3β Ser9 (Cell Signaling Technology), IgM (Thermo
Scientific), and Cry1 and Cry2 antibodies (31).
Clonogenic Cell Survival Assay. The clonogenic survival assay was done as
described previously (32, 33) with some modifications. Cells were seeded at
low density to ensure the formation of 200 colonies per six-well plate
Fig. 3. Role of GSK3β in circadian clock control of NF-κB activity. (A) Immunoblots comparing the levels of phospho-GSK3β in wild-type (WT), CryDKO, p53KO,
and p53KOCryDKO cells. Total GSK3 was examined as a loading control. (B) Immunoblot analysis of phospho-GSK3β levels in p53KO cells transfected with the
indicated siRNAs. (C) Decay kinetics of phospho-GSK3β. Shown are immunoblots of extracts of p53KOCryDKO cells treated with 20 μg/mL of cycloheximide
(CHX) or 5 μg/mL of actinomycin D (ActD) for the indicated times. Immunoblot of total GSK3β is included as a loading control. (D) Effect of GSK3β activity on
NF-κB target gene expression in p53KOCryDKO cells. The cells were preincubated with sodium nitroprusside (SNP), which activates GSK3β through de-
phosphorylation, and then treated with TNFα where indicated, and IAP2 and ICAM transcription levels were determined by quantitative real-time PCR. The
data are normalized to GAPDH levels (±SD, n = 3). *P < 0.005, **P < 0.001. (E and F) Effect of GSK3β activity on TNFα-induced apoptosis (E), and clonogenic
survival (F) in p53KOCryDKO cells without and with SNP treatment to control the phospho-GSK3β levels. (G) Model for the regulation of cytokine initiated NF-κB
antiapoptotic function through the clock-controlled GSK3β activity in p53-deficient tumor cells and the consequence of cryptochrome inactivation.











(Corning). Following plating, cells were kept in growth medium for 10–14 h
and treated with a single dose of TNFα (50 ng/mL). Readily visible colonies
(over 50 cells per colony) formed after a 9- to 10-d incubation were fixed and
counted. The number of observed colonies divided by the number of plated
cells was expressed as cell viability.
mRNA Measurement by Quantitative PCR. RNA was extracted using RNeasy
mini kit (Qiagen) and cDNA was generated using ImProm-II reverse tran-
scription system (Promega). PCR was performed in a 7900HT fast real-time
PCR system (Applied Biosystems) using the 2× sybr green master mix (Applied
Biosystems) with the primers listed in Table S1.
ChIP Assay. Cells treated with TNFα (50 ng/mL) for 30 min were collected
and washed with PBS. ChIP was performed by manufacturer’s instruction
(Sigma) with some exceptions. Protein–DNA complexes incubated with
either an anti-RelA antibody (Santa Cruz Biotechnology) or an equivalent
IgG control (Cell Signaling Technology) were precipitated using protein A/
G-conjugated agarose beads (Calbiochem). Protein–DNA crosslink was
resolved and followed by quantitative real-time PCR (qPCR) using sybr
green master mix (Applied Biosystems). For detection of RelA binding
onto the IAP2 and ICAM1 promoters, the following primers were used
for PCR (for IAP2, 5′ TGTAAGAGCCAAGAGCCTTC and 3′ ACTTCCTCCTCA-
CCCTTGGT; for ICAM1, 5′ CCAGATCTTGAGTGTTGGAA and 3′ CAGCTT-
GTCCTCCTGTCTCC).
Tumor Xenograft Model. Cells were treated ex vivo for 4 h with TNFα (50 ng/
mL), harvested, and resuspended for injection. A total of 2 × 106 cells mixed
with an equal volume of matrigel (BD Biosciences) were inoculated s.c. into
both flanks of 6-wk-old female immunodeficient NOD/SCID mice. The NOD/
SCID mice were bred and kept under defined-flora pathogen-free conditions
at the Animal Facility of the Division of Experimental Radiation Oncology,
University of North Carolina. Tumor volume and body weight were recorded
every 3 d. Tumor size was measured with a caliper in three mutually per-
pendicular diameters (a, b, and c) and the volume was calculated as V = (π/6)
× a × b × c.
MicroPET Imaging. Whole-body images of the biodistribution of 18F-2-
deoxyglucose ([18F]-FDG) tracers in mice was obtained by micropositron
emission tomography (microPET) scans. Mice were kept warm, under gas
anesthesia (2% isoflourane), and injected with [18F]-FDG intraperitoneally.
A 1-h interval for uptake was allowed between probe administration and
microPET scanning. Data were acquired using a Siemens Preclinical Solutions
microPET Focus 220 instrument. MicroPET data were acquired for 10 min
and were reconstructed using statistical maximum a posteriori probability
(MAP) algorithms into multiple frames. The spatial resolution of microPET is
∼1.5-mm, 0.4-mm voxel size. Three dimensional regions of interest (ROIs)
were drawn using AMIDE software (Andreas Loening, Stanford University,
Stanford, CA). Color scale is proportional to tissue concentration with red
being the highest and lower values in yellow, green, and blue.
Statistical Analysis. Values are shown as mean ± SD calculated using a two-
tailed t test.
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Fig. 5. Modulation of antitumorigenic effect of TNFα by cryptochrome.
(A) Tumor growth. NOD/SCID mice were s.c. injected with untreated or
TNFα-treated p53KO cells on the left flank and untreated or TNFα-treated
p53KOCryDKO cells on the right flank, and tumor growth was monitored
for 40 d. Error bars represent means ± SD (n = 10). *P < 0.001. (B) Tumor
metabolism. MicroPET scan recorded 1 h after [18F]-FDG injection on day
38 after xenograft injection. The NOD/SCID mice were injected with TNFα-
treated CryDKO cells in the left flank (*) and p53KOCryDKO cells in the right
flank (**). (Right) Quantification of [18F]-FDG signal calculated as the
ratio of percentage of injected dose (% ID) at the region of interest (ROI,
circle) to the % ID at a background region. Error bars represent means ±
SD (n = 4). The MicroPET scan (Left) is a dorsal view of a representative
mouse.
Fig. 4. The clock regulates NF-κB-dependent apoptosis in p53-deficient
hepatocellular carcinoma. (A–C ) Hep3B (p53−/−) cells. The cells were
transfected with the indicated siRNAs, followed by TNFα treatment and
were then analyzed for expression of NF-κB controlled antiapoptotic
genes by quantitative real-time PCR (A), for apoptosis by immunoblotting
for PARP and cleaved caspase 3 (B), and for clonogenic survival (C ).*P <
0.005, **P < 0.001 (±SD, n = 3). (D) HepG2 (p53+/+) cells. Immunoblots of
extracts from siRNA transfected cells following treatment with TNFα (50
ng/mL, 48 h).
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